⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
GMAB News
Genmab A/S ADS
Bispecific Antibody Drug Conjugates Market Landscape Report 2026: A $2 Billion Opportunity by 2030 with the 1st Approved BsADC by 2028 - Clinical Trials, Regulatory Approvals, Development Platforms
globenewswire.com
AMGN
AZN
GMAB
Bispecific Antibody Market Landscape Report 2026: A Potential $60 Opportunity by 2031 - Insight on More than 550 Clinical Trials - Antibody Dosage, Patent, Price, Sales & Outlook
globenewswire.com
JNJ
AMGN
GMAB
ABBV
AZN
PFE
BMY
REGN
XNCR
ZYME
Genmab A/S Share Capital Reduction
globenewswire.com
GMAB
Major Shareholder Announcement
globenewswire.com
GMAB
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026
globenewswire.com
GMAB
Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer
globenewswire.com
GMAB
Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer
globenewswire.com
GMAB
Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S ®) in Combination with Bevacizumab in Advanced Ovarian Cancer
businesswire.com
GMAB
Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)
globenewswire.com
GMAB
Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
globenewswire.com
GMAB